Cartesian Therapeutics Inc. (RNAC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $193.69M
Last updated: Nov 17, 2026 at 11:05 AM ET
Cartesian Therapeutics Inc. (RNAC) Competitors
The companies most similar to Cartesian Therapeutics are SAB Biotherapeutics (SABS), Cellectis SA (CLLS) and Sutro Biopharma (STRO). By market cap, Cartesian Therapeutics ranks 6th of the 13 companies on this page; Editas Medicine (EDIT) is the largest at $334.92M.
Peer Comparison
RNAC's ROIC of 147.2% is above the peer median of -42.3%, and its revenue growth of -92.9% is below the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Cartesian Therapeutics (RNAC) | $193.69M | N/A | 179.8x | 0.0% | 147.2% | -92.9% | 0.00% |
| SAB Biotherapeutics Inc (SABS) | $266.66M | N/A | N/A | 0.0% | N/A | -62.4% | 0.00% |
| Cellectis SA (CLLS) | $118.86M | N/A | 1.8x | 0.0% | -74.1% | -85.4% | 0.00% |
| Sutro Biopharma (STRO) | $163.03M | N/A | 3.4x | 0.0% | N/A | -6.1% | 0.00% |
| Zentalis Pharmaceuticals Llc (ZNTL) | $167.05M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Galectin Therapeutics Inc (GALT) | $307.59M | N/A | N/A | 0.0% | 671.1% | 0.0% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| Precision BioSciences Inc (DTIL) | $288.76M | N/A | 4.4x | -85.6% | -38.3% | 37272.0% | 0.00% |
| Editas Medicine Inc (EDIT) | $334.92M | N/A | 5.6x | -145.0% | -42.3% | 37.4% | 0.00% |
| Sol Gel Technologies Ltd (SLGL) | $180.46M | N/A | 125.4x | 0.0% | N/A | -96.6% | 0.00% |
| Palisade Bio Inc (PALI) | $201.01M | N/A | 436.8x | 0.0% | N/A | 0.0% | 0.00% |
| Fate Therapeutics Inc (FATE) | $155.74M | N/A | 29.7x | 0.0% | -51.3% | 9.2% | 0.00% |
| Compass Therapeutics Inc. (CMPX) | $139.35M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $176.02M | N/A | 5.0x | 0.0% | -42.3% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Cartesian Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| SAB Biotherapeutics Inc (SABS) | SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. | SABS competitors |
| Cellectis SA (CLLS) | Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors... | CLLS competitors |
| Sutro Biopharma (STRO) | Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. | STRO competitors |
| Zentalis Pharmaceuticals Llc (ZNTL) | Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment... | ZNTL competitors |
| Galectin Therapeutics Inc (GALT) | Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic... | GALT competitors |
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| Precision BioSciences Inc (DTIL) | Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. | DTIL competitors |
| Editas Medicine Inc (EDIT) | Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. | EDIT competitors |
| Sol Gel Technologies Ltd (SLGL) | Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological... | SLGL competitors |
| Palisade Bio Inc (PALI) | Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. | PALI competitors |
| Fate Therapeutics Inc (FATE) | Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. | FATE competitors |
| Compass Therapeutics Inc. (CMPX) | Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple... | CMPX competitors |
Frequently Asked Questions About RNAC
Who are Cartesian Therapeutics' main competitors?
The companies most similar to Cartesian Therapeutics include SAB Biotherapeutics (SABS), Cellectis SA (CLLS), Sutro Biopharma (STRO), Zentalis Pharmaceuticals Llc (ZNTL) and Galectin Therapeutics (GALT), listed from the closest match.
Who is Cartesian Therapeutics' biggest competitor?
Editas Medicine (EDIT) is the largest of the similar companies at $334.92M; SAB Biotherapeutics (SABS) is the closest match by business profile, size, sector and industry.
How does RNAC stock compare with its competitors?
RNAC's P/S is 179.8x against a peer median of 5.0x; its net margin is 0.0% against a peer median of 0.0%.
Which of Cartesian Therapeutics' competitors pays a higher dividend?
Cartesian Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Cartesian Therapeutics bigger than its competitors?
No. Cartesian Therapeutics is 6th by market cap among the 13 companies on this page; the largest is Editas Medicine (EDIT) at $334.92M.
RNAC pages: Overview, Earnings, Forecast, Financials, Competitors